Taletrectinib’s current marketing progress and latest price updates at home and abroad

Taletrectinib (Taletrectinib) is a new, oral ROS1 and NTRKdual-target inhibitors are mainly used to treat ROS1 fusion-positive non-small cell lung cancer (NSCLC). In December 2024, China's National Food and Drug Administration (NMPA) took the lead in conditionally approving the marketing of talatinib for ROS1 Adult patients with advanced stageROS1positiveNSCLC with disease progression after TKItreatment. Subsequently, at the beginning of 2025, its indications were further expanded to patients with ROS1-positive lung cancer who had not received ROS1 targeted therapy. In 2025June, the US FDA also officially approved the drug for marketing, marking its important progress on a global scale.

The reason why talatinib was quickly approved in China and the United States is mainly due to its excellent efficacy in two key phase II clinical trials: TRUST-I and TRUST-II. Studies have shown that in patients who have not received ROS1 inhibitor treatment, the overall response rate (ORR) is as high as 85%and above; and in patients who have progressed after receiving first-generation ROS1 inhibitors such as crizotinib, talatinib still shows strong anti-tumor activity. In addition, the drug's efficacy in patients with brain metastases is also worthy of attention, as it has obvious central nervous system penetration and low central nervous system side effects.

At present, talatinib has completed marketing approval in mainland China, but has not yet fully launched commercial sales. According to some information, its reference price is approximately 8679 yuan (200mg/ bottle) or 10296 yuan (250mg/bottle), but the actual market retail price and the progress of medical insurance negotiations have not yet been publicly determined. As a self-developed "breakthrough treatment" innovative drug, it is expected to be included in the national medical insurance catalog in the future, thereby further reducing patients' out-of-pocket burden and improving accessibility.

In the U.S. market, talatinib with the trade name Ibtrozi has just been approved by the FDA and the official price has not yet been announced. However, considering its targeted therapy positioning and research and development background, its pricing is expected to be close to the level of current first-line ROS1 inhibitors. If it can successfully enter the medical insurance system of the United States and other countries in the future, the burden on patients will be significantly reduced. Overall, talatinib, as one of the representatives of China's original targeted drugs, not only fills an important gap in the field of ROS1-targeted therapy, but also brings more hope to ROS1-positive lung cancer patients around the world.

Reference materials:https://www.fda.gov/drugs/